Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings experienced worse outcomes than observed in trials. Higher toxicity rates ...

As a rough comparison, in a similar trial population glofitamab had an overall response rate of 52%, with 39% complete responses, with 78% of them responding for 12 months or more. “The FDA ...

More information: Tycel Jovelle Phillips et al, Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase ...